Related Experiment Video
Updated: Mar 11, 2026

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis
Published on: August 7, 2018
The role of necroptosis in pulmonary diseases
Kenji Mizumura1, Shuichiro Maruoka1, Yasuhiro Gon1
1Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Abstract:
By regulating the cell number and eliminating harmful cells, programmed cell death plays a critical role in development, homeostasis, and disease. While apoptosis is a recognized form of programmed cell death, necrosis was considered a type of uncontrolled cell death induced by extreme physical or chemical stress. However, recent studies have revealed the existence of a genetically programmed and regulated form of necrosis, termed necroptosis. Necroptosis is defined as necrotic cell death that is dependent on receptor-interacting protein kinase 3 (RIPK3). RIPK3, receptor-interacting protein kinase 1 (RIPK1), and a mixed-lineage kinase domain-like protein (MLKL) form a multiprotein complex called a necrosome. Although necroptosis generally provides a cell-autonomous host defense, on the other hand, cell rupture caused by necroptosis induces inflammation through the release of damage-associated molecular patterns, such as mitochondrial DNA, HMGB1, and IL-1. Previously, necroptosis was considered an alternative to apoptosis, but it is becoming increasingly clear that necroptosis itself is relevant to clinical disease, independent of apoptosis. According to some recent studies, autophagy, a cellular process for organelle and protein turnover, regulates necroptosis. This review outlines the principal components of necroptosis and provides an overview of the emerging importance of necroptosis in the pathogenesis of pulmonary disease, including chronic obstructive pulmonary disease, lung cancer, infection, and sepsis. We also discuss the molecular relationship between necroptosis and autophagy. Strategies targeting necroptosis may yield novel therapies for pulmonary diseases.
Insights
Programmed cell death, necroptosis, is a regulated form of necrosis involving RIPK3. This process, distinct from apoptosis, plays a role in pulmonary diseases and interacts with autophagy.
Area of Science:
- Cellular biology
- Immunology
- Pathogenesis
Background:
- Programmed cell death is crucial for development and homeostasis.
- Necrosis was traditionally viewed as uncontrolled cell death.
- Necroptosis is a newly recognized, regulated form of necrosis dependent on RIPK3.
Purpose of the Study:
- To define necroptosis and its molecular components.
- To review the role of necroptosis in pulmonary diseases.
- To explore the relationship between necroptosis and autophagy.
Main Methods:
- Review of existing literature on necroptosis.
- Analysis of the molecular machinery of necroptosis (RIPK3, RIPK1, MLKL).
- Discussion of necroptosis's role in chronic obstructive pulmonary disease, lung cancer, infection, and sepsis.
Main Results:
- Necroptosis is a regulated necrotic cell death pathway.
- The necrosome complex (RIPK3, RIPK1, MLKL) mediates necroptosis.
- Necroptosis induces inflammation via DAMPs release and is implicated in pulmonary diseases.
Conclusions:
- Necroptosis is a clinically relevant process independent of apoptosis.
- Autophagy modulates necroptosis.
- Targeting necroptosis may offer new therapeutic strategies for pulmonary diseases.
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Pulmonary Cycle: Exhalation
Pneumonia II: Pathophysiology

